Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: Sadif Analytics Prime
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

JCL Bioassay Corp Amends Consolidated Mid-year Outlook for FY 2014


Tuesday, 5 Nov 2013 01:30am EST 

JCL Bioassay Corp announced that it has raised its consolidated mid-year outlook for revenue from JPY 880 million to JPY 970 million, ordinary profit from a loss of JPY 46 million to a loss of JPY 23 million, but lowered the outlook for operating profit from a loss of JPY 28 million to a loss of JPY 55 million, net profit from a loss JPY 29 million to a loss of JPY 47 million and earning per share from a loss of JPY 8.99 to a loss of JPY 13.80, for the fiscal year ending March 2014. The positive outlook is due to the increased sales and the cost reduction, and the negative outlook due to the decreased sales in subsidiary. 

Company Quote

459.0
13.0 +2.91%
19 Dec 2014